NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Individuals Who Provided Content Development and/or Authorship Assistance

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Lee-may Chen, MD, Panel Member
Heidi G. Gray, MD, Panel Member
Steven W. Remmenga, MD, Panel Member
Emese Zsiros, MD, PhD, Panel Member
Mary A. Dwyer, MS, CGC, Senior Director, Guidelines Operations, NCCN
Lisa Hang, PhD, Oncology Scientist/Medical Writer, NCCN

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Deborah K. Armstrong, MD, Panel Chair, has disclosed receiving grant/research support from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc., Pfizer Inc., and Syndax Pharmaceuticals Inc.; and serving as a scientific advisor for AstraZeneca Pharmaceuticals LP and Johnson & Johnson.
Ronald D. Alvarez, MD, MBA, Panel Vice Chair, has disclosed serving as a scientific advisor for AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, and Myriad Genetic Laboratories, Inc.
Floor J. Backes, MD, Panel Member, has disclosed receiving grant/research support from AstraZeneca Pharmaceuticals LP, BeiGene, Clovis Oncology, Eisai Inc., ImmunoGen, Inc., Merck & Co., Inc., and Natera, Inc.; and serving as a scientific advisor for Agenus Inc., AstraZeneca Pharmaceuticals LP, Clovis Onocology, Eisai Inc., GlaxoSmithKline, ImmunoGen, Inc., and Merck & Co., Inc.
Eric L. Eisenhauer, MD, Panel Member, has disclosed receiving consulting fees from Seagen Inc.
David M. Gershenson, MD, Panel Member, has disclosed serving as a scientific advisor for Genentech, Inc., Onconova Therapeutics, and Verastem Oncology; owning equity interest/stock options in Bristol-Myers Squibb Company, Johnson & Johnson, and Procter & Gamble Company; receiving grant/research support from the Novartis Pharmaceuticals Corporation; and receiving royalty income from Elsevier.
Amer Karam, MD, Panel Member, has disclosed serving in a product/speakers’ bureau for AstraZeneca Pharmaceuticals LP and GlaxoSmithKline; and receiving consulting fees from Clovis Oncology.
Charles Leath III, MD, MSPH, Panel Member, has disclosed receiving consulting fees from AbbVie Inc., Celsion Corporation, Clovis Oncology, Eisai Inc., GlaxoSmithKline, ImmunoGen, Inc., Merck & Co., Inc., Natera, Inc., PAREXEL International Corporation, and Seattle Genetics, Inc.; and receiving grant/research support from AbbVie, Inc., Agenus Inc., Celsion Corporation, GlaxoSmithKline, ImmunoGen, Inc., Merck & Co., Inc., and Seattle Genetics, Inc.
Joyce Liu, MD, MPH, Panel Member, has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc., EpsilaBio, Genentech, Inc., GlaxoSmithKline, and Regeneron Pharmaceuticals, Inc.
Daniela Matei, MD, Panel Member, has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, Eisai Inc., GlaxoSmithKline, and Seagen Inc.; receiving grant/research support from AbbVie, Inc. and PinotBio Inc.; and serving as a scientific advisor for GlaxoSmithKline and KIYATEC Inc.
David S. Miller, MD, Panel Member, has disclosed receiving grant/research support from Advaxis Inc., Advenchen Laboratories, LLC, Aeterna Zentaris Inc., Agenus Inc., Akesobio, Aprea Therapeutics AB, AstraZeneca Pharmaceuticals LP, EMD Serono Research & Development Institute, ImmunoGen, Inc., Incyte Corporation, Janssen Pharmaceutica Products, LP, Karyopharm Therapeutics, Leap Therapeutics, Inc., Mateon Therapeutics, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, NVISION, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Syros Pharmaceuticals, TESARO, Inc., TRACON Pharmaceuticals, Inc., US Biotest, Inc., and Xenetic Biosciences, Inc.; serving as a consultant/advisor for AbbVie, Inc., Agenus Inc., AstraZeneca Pharmaceuticals LP, Asymmetric Therapeutics, LLC, Eisai Inc., Eisai Europe Limited, EMD Serono Inc., GlaxoSmithKline, ImmunoGen, Inc., Incyte Corporation, iTeos Belgium SA, Karyopharm Therapeutics, Merck & Co., Inc., Myriad Genetic Laboratories, Inc., Novartis Pharmaceuticals Corporation, Novocure, Seagen Inc., and Tarveda Therapeutics; and serving on a speaker/product bureau for Clovis Oncology and Genentech Inc.
Premal H. Thaker, MD, Panel Member, has disclosed serving as a scientific advisor for Agenus Inc., AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc., GlaxoSmithKline, Merck & Co., Inc., Mersana Therapeutics Inc., Novartis Pharmaceuticals Corporation, Novocure, and Seagen Inc.; receiving grant/research support from GlaxoSmithKline and Merck serving on a data safety monitoring board for and receiving consulting fees from Celsion Corporation; and serving on a steering committee for Novocure.
Andrea Wahner Hendrickson, MD, Panel Member, has disclosed receiving grant/research support from Amgen Inc., Aravive, Inc., AstraZeneca Pharmaceuticals LP, Harpoon Therapeutics, Inc., ProLynx, and TESARO, Inc.; and serving as a scientific advisor for Oxcia AB.
Theresa L. Werner, MD, Panel Member, has disclosed serving as a scientific advisor for Mersana Therapeutics Inc.

View all of the conflicts of interest for the NCCN Guidelines panel

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.